Like SRP9001 Sareptas lead investigational gene transfer therapy for Duchenne and the Companys five other LGMD programs the LGMD2A program uses the AAVrh74 vector designed to systematically and robustly deliver treatment to skeletal muscle making it an ideal candidate to treat muscle disease